Open Access<p>Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma</p>
Author(s) -
Ying Zong,
Zhi Peng,
Xicheng Wang,
Ming Lu,
Lin Shen,
Jun Zhou
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s263773
Subject(s) - gemcitabine , medicine , nab paclitaxel , paclitaxel , pancreatic ductal adenocarcinoma , chemotherapy , oncology , adverse effect , adenocarcinoma , gastroenterology , pancreatic cancer , cancer
Nab-paclitaxel plus gemcitabine (nab-P/G) has been established as a standard first-line treatment in metastatic pancreatic ductal adenocarcinoma (PDAC). S-1, as an oral fluoropyrimidine derivative, demonstrated effective for PDAC. This study aimed to evaluate the efficacy and safety of first-line chemotherapy with nab-paclitaxel plus S-1 (nab-P/S) versus nab-P/G in patients with advanced PDAC.